MedTrace Logo

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

NCT04873141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2021-05-05

No results posted yet for this study

Summary

Tocilizumab (TCZ), interleukin-6 (IL-6), newly appeared as treatment of cytokine release syndrome (CRS) in patients with severe covid-19 associated pneumonia. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients.

Conditions

Interventions

DRUG

Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)

Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).

Sponsors & Collaborators

  • Shaheed Zulfiqar Ali Bhutto Medical University

    lead OTHER

Principal Investigators

  • Muhammad Hassan, MD · Shaheed Zulfiqar Ali Bhutto Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2020-06-22
Completion
2020-06-22
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04873141 on ClinicalTrials.gov